Cantor Fitzgerald reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note released on Sunday. Cantor Fitzgerald currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

“Cantor Fitzgerald will host a physician conference call on Tuesday to provide perspective on pitolisant as it relates to JAZZ’s sleep franchise. The call is at 1:00pm EST and the dial in number can be obtained from your Cantor sales rep. Note that the call will be 30 minutes in duration. Questions for the consultant can be emailed to [email protected]”,” Cantor Fitzgerald’s analyst wrote.

JAZZ has been the topic of several other reports. HC Wainwright initiated coverage on Jazz Pharmaceuticals in a research report on Friday, August 25th. They set a neutral rating and a $144.00 price target on the stock. Morgan Stanley initiated coverage on Jazz Pharmaceuticals in a research report on Thursday, October 5th. They set an equal weight rating and a $155.00 price target on the stock. FBR & Co initiated coverage on Jazz Pharmaceuticals in a research report on Thursday, October 19th. They set a buy rating and a $206.00 price target on the stock. Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 31st. Finally, Cowen set a $190.00 price target on Jazz Pharmaceuticals and gave the company a buy rating in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $180.25.

Jazz Pharmaceuticals (NASDAQ:JAZZ) opened at $135.75 on Friday. Jazz Pharmaceuticals has a 1 year low of $99.28 and a 1 year high of $163.75. The stock has a market capitalization of $8,284.56, a price-to-earnings ratio of 17.34, a PEG ratio of 0.89 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.

In other news, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the sale, the director now owns 1,365 shares of the company’s stock, valued at $181,804.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,352 shares of company stock valued at $1,417,763. 4.30% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. Toronto Dominion Bank boosted its position in shares of Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares during the period. US Bancorp DE boosted its position in shares of Jazz Pharmaceuticals by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the period. Gargoyle Investment Advisor L.L.C. acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $206,000. Advisor Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 62.4% in the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 550 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $211,000. 91.30% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Cantor Fitzgerald” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/06/jazz-pharmaceuticals-jazz-buy-rating-reiterated-at-cantor-fitzgerald.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.